错配修复缺陷型甲状腺未分化癌的临床病理特征
该研究对2003至2017年确诊的28例甲状腺未分化癌(ATC)组织块行错配修复(MMR)蛋白免疫组化,识别出4例(14%)MMR蛋白缺陷(MMR-D)肿瘤,均完全丢失MSH2与MSH6。MMR-D患者初诊时远处转移较少(p=0.035)且生存显著优于MMR蛋白完整(MMR-I)者(p=0.033)。
要点
- 28例ATC中4例(14%)为MMR-D,均完全丢失MSH2与MSH6。
- MMR-D患者初诊远处转移更少(p=0.035),生存显著更优(p=0.033)。
- 4例MMR-D患者均生存超过1年,但样本量小需谨慎解读。
核心结论
- MMR-D肿瘤占该ATC队列的14%,结果提示MMR状态在ATC中可能具有预后意义。
- 鉴于队列中MMR-D ATC数量少,上述发现须谨慎解读。
研究设计与样本
- 回顾性队列研究,纳入2003至2017年确诊且有组织块的28例甲状腺未分化癌(ATC)。
- 采用免疫组化检测MMR蛋白以识别MMR-D肿瘤,并以靶向二代测序确定分子改变。
- 将MMR-D肿瘤的临床病理特征、分子结果与临床结局与MMR-I肿瘤比较。
主要发现
- 4例(14%)为MMR-D ATC,均显示MSH2和MSH6完全丢失,MLH1和PMS2表达完整。
- 4例MMR-D肿瘤中3例有MSH2突变,二代测序显示超突变表型。
- 4例MMR-D患者(2例男性;诊断时平均年龄64岁)均表现为IVB期疾病。
- MMR-D与MMR-I在肿瘤大小、大体甲状腺外侵犯率、淋巴结转移率或切缘阳性率上无差异。
- MMR-D患者初诊时远处转移较少(p=0.035),但半数最终发生远处转移;MMR-D肿瘤组织学上无区别。
关键数值与推荐
- MMR-D患者均生存超过1年:1例于15个月死于疾病,其余3例末次随访时存活,生存期分别为19、38和48个月。
- MMR-D ATC患者生存显著优于MMR-I肿瘤患者(p=0.033),仅分析初诊IVB期患者时该差异仍存在(p=0.030)。
临床怎么用
- 对ATC可考虑行MMR蛋白免疫组化检测以识别MMR-D亚型,辅助预后判断。
- MMR-D ATC患者生存可能优于MMR-I者,但需结合样本量小的局限谨慎用于临床决策。
局限性
- MMR-D ATC病例数少(4例),结果须谨慎解读。
- 为单队列回顾性研究,样本量共28例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Prior studies have reported mutations in mismatch repair (MMR) genes in a small subset of anaplastic thyroid carcinomas (ATC). The aim of this study was to identify MMR-protein-deficient (MMR-D) ATC and investigate their histopathologic features and clinical outcome. Methods: A cohort of 28 ATC diagnosed between 2003 and 2017 with tissue blocks available were evaluated. Immunohistochemistry for MMR proteins was performed to identify MMR-D tumors. Clinicopathologic features, molecular findings (determined by a targeted next-generation sequencing assay), and clinical outcome data for MMR-D tumors were recorded and compared to that of MMR-protein-intact (MMR-I) tumors. Results: There were four (14%) MMR-D ATC, all of which showed complete loss of MSH2 and MSH6 with intact expression of MLH1 and PMS2. Three of these tumors had MSH2 mutations and a hypermutated phenotype by next-generation sequencing. All four patients (two male; Mage at diagnosis = 64 years) presented with stage IVB disease (i.e., gross extrathyroidal extension or a lymph node metastasis at presentation). There were no differences in tumor size or rates of gross extrathyroidal extension, lymph node metastases, or positive resection margins between MMR-D and MMR-I ATC. Patients with MMR-D tumors were less likely to have distant metastatic disease at presentation (p = 0.035), although half did eventually develop distant metastases. MMR-D tumors were not histologically distinct. All four patients with MMR-D tumors lived for more than one year. One patient died of disease at 15 months, while the remaining three were alive at last follow-up, with survival of 19, 38, and 48 months. Patients with MMR-D ATC had significantly better survival compared to those with MMR-I tumors (p = 0.033), which was maintained when considering only patients with stage IVB disease at presentation (p = 0.030). Conclusion: MMR-D tumors comprised 14% of this ATC cohort. Although the findings must be interpreted with caution given the small number of MMR-D ATC in the cohort, the results suggest that MMR status may be prognostically significant in ATC.
引用
- Wong KS, Lorch JH, Alexander EK, et al. Clinicopathologic Features of Mismatch Repair-Deficient Anaplastic Thyroid Carcinomas. Thyroid. 2019. PMID: 30869569. doi:10.1089/thy.2018.0716
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。